Highlights of 2025: the B-side of LEF1

IF 3.3 4区医学 Q3 CELL BIOLOGY

Immunology & Cell Biology Pub Date : 2026-07-03 Epub Date: 2026-05-03 DOI:10.1111/imcb.70129

Isabella Naylor, Adrian Y S Lee, Joanne Reed, Qian Shen

引用次数: 0

Abstract

In this article of the Highlights of 2025 series, we review the latest discovery of LEF1 function in B cell biology. These discoveries provide novel insights into the LEF1 function on B cell maintenance in cancer and autoimmunity, uncovering new opportunities for the development of a more specific B cell targeting approach.

Abstract Image

查看原文本刊更多论文

2025年的亮点：LEF1的b面。

在2025系列的这篇文章中，我们回顾了在B细胞生物学中LEF1功能的最新发现。这些发现为LEF1在癌症和自身免疫中对B细胞维持的功能提供了新的见解，为开发更特异性的B细胞靶向方法提供了新的机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunology & Cell Biology 医学-免疫学

CiteScore

7.50

自引率

2.50%

发文量

审稿时长

4-8 weeks

期刊介绍： The Australasian Society for Immunology Incorporated (ASI) was created by the amalgamation in 1991 of the Australian Society for Immunology, formed in 1970, and the New Zealand Society for Immunology, formed in 1975. The aim of the Society is to encourage and support the discipline of immunology in the Australasian region. It is a broadly based Society, embracing clinical and experimental, cellular and molecular immunology in humans and animals. The Society provides a network for the exchange of information and for collaboration within Australia, New Zealand and overseas. ASI members have been prominent in advancing biological and medical research worldwide. We seek to encourage the study of immunology in Australia and New Zealand and are active in introducing young scientists to the discipline.